Introduction:
The Novo Nordisk Foundation has partnered with CARB-X to invest up to US$25m in supporting the early-stage development of drugs, vaccines, and diagnostics to combat drug-resistant bacterial infections. The partnership aims to address the funding gap in antibacterial product development and accelerate the translation of promising research into medical interventions.
- The Novo Nordisk Foundation is committing up to US$25m to support the development of drugs, vaccines, and diagnostics to fight drug-resistant bacterial infections.
- Most pharmaceutical companies have prioritized more lucrative therapeutic areas, resulting in academic spin-outs and small companies in need of grants and guidance for early-stage development.
- The partnership with CARB-X aims to fill the funding gap and support the translation of promising ideas for antibacterial products from basic research to clinical development.
- CARB-X has funded 93 projects in 12 countries since 2016, with 19 projects advancing to clinical trials and two diagnostic products reaching the market.
- The Novo Nordisk Foundation’s commitment aligns with its initiative to reduce the use of antibiotics through the development of vaccines against respiratory infections.
Conclusion:
The partnership between the Novo Nordisk Foundation and CARB-X signifies a significant investment in combatting drug-resistant bacterial infections. By providing funding and guidance to early-stage product developers, the partnership aims to accelerate the translation of research into effective medical interventions. This commitment is crucial, considering the inadequate clinical pipeline and the limited private investments in innovative antibiotics. By addressing the funding gap and supporting the development of antibacterial products, the partnership can contribute to reducing the impact of drug-resistant infections and protecting public health.
